Symbols / PXMD $0.00 +0.00% PaxMedica, Inc.

Healthcare • Biotechnology • United States • PNK
PXMD Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

Fundamentals
Scroll to Statements
Market Cap 63.13K Enterprise Value -381.72K Income -13.49M Sales — Book/sh -0.18 Cash/sh 0.00
Dividend Yield — Payout 0.00% Employees 6 IPO — P/E 0.00 Forward P/E -0.00
PEG — P/S — P/B -0.00 P/C — EV/EBITDA — EV/Sales —
Quick Ratio 0.20 Current Ratio 0.36 Debt/Eq — LT Debt/Eq — EPS (ttm) 2.44 EPS next Y -1.09
EPS Growth — Revenue Growth — Earnings — ROA -3.70% ROE — ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 126.26M Shs Float — Short Float 8.62%
Short Ratio 0.10 Short Interest — 52W High 0.02 52W Low 0.00 Beta -32.91 Avg Volume 2.42K
Volume 300.00 Target Price — Recom None Prev Close $0.00 Price $0.00 Change 0.00%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-0.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-12-04 init HC Wainwright & Co. — → Buy $3
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
16.15
+52.25%
10.60
+47.33%
7.20
Research And Development
3.91
+119.02%
1.79
-19.65%
2.22
Selling General And Administration
12.23
+38.71%
8.82
+77.29%
4.97
General And Administrative Expense
12.23
+38.71%
8.82
+77.29%
4.97
Other Gand A
12.23
+38.71%
8.82
+77.29%
4.97
Total Expenses
16.15
+52.25%
10.60
+47.33%
7.20
Operating Income
-16.15
-52.25%
-10.60
-47.33%
-7.20
Total Operating Income As Reported
-16.15
-52.25%
-10.60
-47.33%
-7.20
EBITDA
-18.28
-23.55%
-14.80
-99.33%
-7.42
Normalized EBITDA
-18.23
-9.38%
-16.67
-131.54%
-7.20
EBIT
-18.28
-23.55%
-14.80
-99.33%
-7.42
Total Unusual Items
-0.05
-102.43%
1.87
+941.09%
-0.22
Total Unusual Items Excluding Goodwill
-0.05
-102.43%
1.87
+941.09%
-0.22
Special Income Charges
-0.05
+71.79%
-0.16
-369.77%
0.06
Other Special Charges
0.05
-71.79%
0.16
+369.77%
-0.06
Net Income
-18.29
-23.56%
-14.80
-44.70%
-10.23
Pretax Income
-18.29
-23.56%
-14.80
-44.70%
-10.23
Net Non Operating Interest Income Expense
-0.01
+97.69%
-0.40
+85.87%
-2.81
Interest Expense Non Operating
0.01
+75.00%
0.01
-99.81%
2.81
Net Interest Income
-0.01
+97.69%
-0.40
+85.87%
-2.81
Interest Expense
0.01
+75.00%
0.01
-99.81%
2.81
Other Income Expense
-2.14
+43.82%
-3.80
-1586.91%
-0.23
Other Non Operating Income Expenses
-2.09
+63.18%
-5.68
-233460.08%
-0.00
Gain On Sale Of Security
—
2.04
+820.08%
-0.28
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-18.29
-23.56%
-14.80
-44.70%
-10.23
Net Income From Continuing Operation Net Minority Interest
-18.29
-23.56%
-14.80
-44.70%
-10.23
Net Income From Continuing And Discontinued Operation
-18.29
-23.56%
-14.80
-44.70%
-10.23
Net Income Continuous Operations
-18.29
-23.56%
-14.80
-44.70%
-10.23
Normalized Income
-18.24
-9.40%
-16.68
-66.66%
-10.01
Net Income Common Stockholders
-18.29
-23.56%
-14.80
-44.70%
-10.23
Diluted EPS
-11.00
+61.79%
-28.79
-10.69%
-26.01
Basic EPS
-11.00
+61.79%
-28.79
-10.69%
-26.01
Basic Average Shares
1.66
+223.37%
0.51
+31.14%
0.39
Diluted Average Shares
1.66
+223.37%
0.51
+31.14%
0.39
Diluted NI Availto Com Stockholders
-18.29
-23.56%
-14.80
-44.70%
-10.23
Total Other Finance Cost
—
0.39
—
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
5.68
+157.69%
2.20
+239.72%
0.65
Current Assets
5.68
+157.69%
2.20
+396.37%
0.44
Cash Cash Equivalents And Short Term Investments
4.71
+147.68%
1.90
+328.27%
0.44
Cash And Cash Equivalents
4.71
+147.68%
1.90
+328.27%
0.44
Cash Financial
4.71
+147.68%
1.90
+328.27%
0.44
Receivables
0.00
0.00
—
Accounts Receivable
0.00
0.00
—
Other Current Assets
0.97
+220.66%
0.30
—
Total Non Current Assets
0.00
0.00
-100.00%
0.20
Non Current Deferred Assets
—
0.00
-100.00%
0.20
Total Liabilities Net Minority Interest
2.30
+9.54%
2.10
-80.52%
10.76
Current Liabilities
1.80
-14.33%
2.10
-80.52%
10.76
Payables And Accrued Expenses
1.01
-20.09%
1.26
-11.04%
1.42
Payables
0.83
+11.90%
0.74
+0.67%
0.74
Accounts Payable
0.81
+12.44%
0.72
-1.94%
0.74
Current Accrued Expenses
0.18
-65.85%
0.52
-23.74%
0.68
Pensionand Other Post Retirement Benefit Plans Current
0.79
+57.45%
0.50
-26.41%
0.68
Current Debt And Capital Lease Obligation
—
0.17
—
Current Debt
—
0.17
—
Other Current Borrowings
—
0.17
—
Other Current Liabilities
—
0.16
-98.28%
9.34
Total Non Current Liabilities Net Minority Interest
0.50
0.00
0.00
Non Current Deferred Liabilities
0.50
0.00
—
Non Current Deferred Revenue
0.50
0.00
—
Stockholders Equity
3.39
+3011.28%
0.11
+101.08%
-10.11
Common Stock Equity
3.39
+3011.42%
0.11
+101.08%
-10.11
Capital Stock
0.00
+880.26%
0.00
-92.09%
0.00
Common Stock
0.00
+942.25%
0.00
-89.73%
0.00
Preferred Stock
0.00
+0.00%
0.00
-98.15%
0.00
Share Issued
7.40
+945.41%
0.71
+20.16%
0.59
Ordinary Shares Number
7.40
+945.41%
0.71
+20.16%
0.59
Additional Paid In Capital
55.41
+63.71%
33.85
+283.41%
8.83
Retained Earnings
-52.03
-54.21%
-33.74
-78.16%
-18.94
Total Equity Gross Minority Interest
3.39
+3011.28%
0.11
+101.08%
-10.11
Total Capitalization
3.39
+3011.28%
0.11
+101.08%
-10.11
Working Capital
3.89
+3470.84%
0.11
+101.05%
-10.31
Invested Capital
3.39
+1098.94%
0.28
+102.79%
-10.11
Total Debt
—
0.17
—
Net Tangible Assets
3.39
+3011.28%
0.11
+101.08%
-10.11
Tangible Book Value
3.39
+3011.42%
0.11
+101.08%
-10.11
Dueto Related Parties Current
0.02
-7.50%
0.02
+2566.67%
0.00
Interest Payable
—
—
0.00
Preferred Stock Equity
0.00
+0.00%
0.00
-98.15%
0.00
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-10.77
-77.37%
-6.07
-10.13%
-5.51
Cash Flow From Continuing Operating Activities
-10.77
-77.37%
-6.07
-10.13%
-5.51
Net Income From Continuing Operations
-18.29
-23.56%
-14.80
-44.70%
-10.23
Other Non Cash Items
0.09
-82.50%
0.53
-81.26%
2.81
Stock Based Compensation
5.20
+17.81%
4.42
+230.73%
1.34
Operating Gains Losses
0.07
-98.03%
3.63
+809.82%
0.40
Gain Loss On Investment Securities
0.03
-99.25%
3.47
+769.30%
0.40
Unrealized Gain Loss On Investment Securities
1.82
+1566.11%
0.11
+162.11%
-0.18
Change In Working Capital
0.33
+563.08%
0.05
-85.69%
0.35
Change In Prepaid Assets
-0.67
0.00
—
Change In Payables And Accrued Expense
0.50
+42.07%
0.35
+0.30%
0.35
Change In Accrued Expense
0.05
-80.53%
0.24
+135.08%
0.10
Change In Payable
0.45
+298.31%
0.11
-54.38%
0.25
Change In Account Payable
0.45
+298.31%
0.11
-54.38%
0.25
Change In Other Working Capital
0.50
—
—
Change In Other Current Assets
0.00
+100.00%
-0.30
0.00
Financing Cash Flow
13.58
+80.33%
7.53
+55.78%
4.83
Cash Flow From Continuing Financing Activities
13.58
+80.33%
7.53
+55.78%
4.83
Net Issuance Payments Of Debt
2.45
+97.72%
1.24
0.00
Issuance Of Debt
3.20
+157.86%
1.24
0.00
Repayment Of Debt
-0.75
0.00
—
Long Term Debt Issuance
—
—
0.00
Net Long Term Debt Issuance
—
—
0.00
Short Term Debt Issuance
3.20
+157.86%
1.24
0.00
Short Term Debt Payments
-0.75
0.00
—
Net Short Term Debt Issuance
2.45
+97.72%
1.24
0.00
Net Common Stock Issuance
11.95
+98.34%
6.02
+20.46%
5.00
Common Stock Payments
-0.20
-459.99%
-0.04
—
Repurchase Of Capital Stock
-0.20
-459.99%
-0.04
—
Net Other Financing Charges
-0.82
-2249.43%
-0.04
+79.03%
-0.17
Changes In Cash
2.81
+92.67%
1.46
+314.53%
-0.68
Beginning Cash Position
1.90
+328.27%
0.44
-60.48%
1.12
End Cash Position
4.71
+147.68%
1.90
+328.27%
0.44
Free Cash Flow
-10.77
-77.37%
-6.07
-10.13%
-5.51
Change In Interest Payable
—
—
0.00
Common Stock Issuance
11.95
+98.34%
6.02
+20.46%
5.00
Issuance Of Capital Stock
11.95
+88.93%
6.32
+26.46%
5.00
Net Preferred Stock Issuance
0.00
-100.00%
0.30
0.00
Preferred Stock Issuance
0.00
-100.00%
0.30
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category